Bevacizumab ± irinotecan beneficial for glioblastoma

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1640, 2008-01, pp. : 1-1

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Irinotecan and bevacizumab in recurrent glioblastoma multiforme

By Jakobsen Jan Nyrop Hasselbalch Benedikte Stockhausen Marie-Thééréése Lassen Ulrik Poulsen Hans Skovgaard

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 5, 2011-04 ,pp. : 825-833

Informa Healthcare

Access to resources Recommend Favorite

A retrospective observational analysis to evaluate the off-label use of bevacizumab alone or with irinotecan in recurrent glioblastoma

By Cecchi Michele

International Journal of Clinical Pharmacy, Vol. 35, Iss. 3, 2013-06 ,pp. : 483-487

Springer Publishing Company

Access to resources Recommend Favorite

Bevacizumab: In Previously Treated Glioblastoma

By Moen Marit D.

Drugs, Vol. 70, Iss. 2, 2010-01 ,pp. : 181-189

Adis International

Access to resources Recommend Favorite

Bevacizumab/fluorouracil/irinotecan: Ischaemic colitis: case report

Reactions Weekly, Vol. 1, Iss. 1169, 2007-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?

By Seystahl Katharina Weller Michael

Expert Opinion on Investigational Drugs, Vol. 21, Iss. 5, 2012-05 ,pp. : 605-617

Informa Healthcare

Access to resources Recommend Favorite